8.5 C
New York
Monday, March 23, 2026

First Patient Dosed in Pivotal Phase 3 Trial for Lung Cancer Drug by ArriVent


ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles